Half (50 percent) of a sample of health care industry C-suite executives surveyed last month expect the Biden administration to “formally obligate drug manufacturers to offer 340B pricing,” consulting firm Advis reports in its first health care industry leadership survey of 2021. Advis posed the question amid headlines about drug manufacturers denying or placing conditions on 340B pricing on their products dispensed by contract pharmacies.
Forty-two percent of the 140 executives that Advis surveyed said they expect the new administration to “expand 340B eligibility to more patients, pharmacies, and healthcare entity types.” Forty-one percent expect Biden to “create new, comprehensive 340B program rules and regulations to address current ambiguities.” The U.S. Health Resources and Services Administration (HRSA) says that, due to its lack of comprehensive regulatory authority over 340B, its power to enforce certain program policies is limited.
Half (50 percent) of a sample of health care industry C-suite executives surveyed last month expect the Biden administration to “formally obligate drug manufacturers to offer 340B pricing,” consulting firm Advis reports in its first health care industry leadership survey of 2021. Advis posed the question amid headlines about drug manufacturers denying or placing conditions on 340B pricing on their products dispensed by contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
